This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sotrovimab parenteral


Infusion of sotrovimab.

Drugs List

  • sotrovimab 500mg/8ml solution for infusion
  • XEVUDY 500mg/8ml concentrate for solution for infusion
  • Therapeutic Indications


    Coronavirus disease 2019 (COVID-19) - treatment

    Treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.


    Patients should be monitored during and post intravenous infusion in accordance with local guidelines.

    It is recommended that sotrovimab is administered with 5 days of onset of symptoms of COVID-19. Patients are advised to self-isolate for a period of time from onset of symptoms in accordance with national COVID-19 guidelines and in order to minimise transmission of coronavirus.


    500mg once only as an intravenous infusion.


    Children 12 years and over and weighing at least 40kg
    500mg once only as intravenous infusion.


    For intravenous infusion only.


    Children under 12 years
    Children with body weight under 40kg

    Precautions and Warnings


    Treatment to be prescribed and administered by a specialist
    Concentrate must be diluted and used as an infusion
    Record name and batch number of administered product
    Reduce infusion rate if mild to moderate infusion reaction occurs
    Resuscitation facilities must be immediately available
    Monitor for hypersensitivity reactions - risk of severe reactions
    Discontinue if severe hypersensitivity reactions occur

    Hypersensitivity reactions, including serious and/or life threatening reactions such as anaphylaxis have been reported following treatment with sotrovimab. Hypersensitivity reactions typically occur within 24 hours of infusion. If signs and symptoms of severe hypersensitivity reactions occur, administration should be discontinued immediately and appropriate treatment and/or supportive care should be initiated.

    Pregnancy and Lactation


    Use sotrovimab with caution during pregnancy.

    The manufacturer advises that sotrovimab may be used during pregnancy where the expected benefit to the mother justifies the risk to the foetus. At the time of writing there is no data from the use of sotrovimab during pregnancy. As sotrovimab is a human immunoglobulin G (IgG), animal studies have not been evaluated with respect to reproductive toxicity. No off-target binding was detected in a cross-reactive binding assay. There is potential for placental transfer from the mother to the developing foetus.


    Use sotrovimab with caution during breastfeeding.

    The manufacturer advises that the decision on whether to breastfeed during treatment or to abstain from sotrovimab therapy should take into account the benefit of breastfeeding for the child and the benefit of therapy for the patient. At the time of writing there are no data on the excretion of sotrovimab in human milk. Large molecular weight suggests limited excretion into milk. The potential treatment benefit or risk to the newborn or infants via breastfeeding is not known. Breastfed infants should be monitored for adequate feeding and hypersensitivity reactions.

    Side Effects

    Hypersensitivity reactions
    Infusion-related symptoms
    Skin reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2022

    Reference Sources

    Summary of Product Characteristics: Xevudy 500mg concentrate for solution for infusion. GlaxoSmithKline UK Limited. Revised September 2022.

    NICE Evidence Services Available at: Last accessed: 17 October 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.